Merck MRK
NYSE MRK
$145.93 +0.74 (+0.51%)
As of: Oct 16, 2026 · 3:59 PM EDT

Merck (MRK) Income from Continuing Operations (2009 - 2026)

Updated

Merck's Income from Continuing Operations came in at -$1.34 billion for Q2 2026, compared with $4.43 billion a year earlier.

Analysis

Merck (MRK) Income from Continuing Operations (2009 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Merck reported Income from Continuing Operations of $3.17 billion, down 80.7% year-over-year; for FY2025, it was $18.26 billion, up 6.6% from FY2024.

  • Income from Continuing Operations carries a five-year compound annual growth rate of 32.2% (FY2020 to FY2025).
  • Going back by year, Income from Continuing Operations was $17.13 billion in FY2024, $377 million in FY2023 (-97.4%), $14.53 billion in FY2022 (+17.5%) and $12.36 billion in FY2021 (+173.2%).
  • The five-year range for quarterly Income from Continuing Operations is -$5.97 billion (Q2 2023) to $5.79 billion (Q3 2025).
  • Year-over-year, Income from Continuing Operations increased in two of the last five quarters, with growth averaging 3.3%.
  • The fastest year-over-year change in Income from Continuing Operations over five years came in Q2 2022 (growth of 225.3%), and the weakest in Q1 2023 (a decline of 34.5%).
  • Business Quant data shows MRK's Income from Continuing Operations at -$4.24 billion (Q1 2026), $2.96 billion (Q4 2025) and $5.79 billion (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Eli Lilly 1,122.91 Bn 1,091.50 Bn 19.71 Bn 7.10 Bn
2 Johnson & Johnson 615.09 Bn 533.62 Bn 17.26 Bn 5.53 Bn
3 AbbVie 504.75 Bn 477.86 Bn 12.70 Bn 3.62 Bn
4 Merck 360.18 Bn 314.55 Bn 12.21 Bn -1.34 Bn
5 Novartis Ag 292.05 Bn 256.04 Bn 11.24 Bn 3.26 Bn
6 Astrazeneca 256.09 Bn 229.78 Bn 12.86 Bn 2.51 Bn
7 Amgen 233.63 Bn 189.02 Bn 7.24 Bn 2.38 Bn
8 Gilead Sciences 194.49 Bn 168.69 Bn 6.22 Bn -10.50 Bn
9 Pfizer 168.35 Bn 114.99 Bn 10.94 Bn -246.00 Mn
10 Vertex Pharmaceuticals 126.70 Bn 98.70 Bn 2.84 Bn 1.10 Bn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -1.34 Bn
Mar 31, 2026 -4.24 Bn
Dec 31, 2025 2.96 Bn
Sep 30, 2025 5.79 Bn
Jun 30, 2025 4.43 Bn
Mar 31, 2025 5.09 Bn
Dec 31, 2024 3.74 Bn
Sep 30, 2024 3.16 Bn
Jun 30, 2024 5.46 Bn
Mar 31, 2024 4.77 Bn
Dec 31, 2023 -1.23 Bn
Sep 30, 2023 4.75 Bn
Jun 30, 2023 -5.97 Bn
Mar 31, 2023 2.83 Bn
Dec 31, 2022 3.02 Bn
Sep 30, 2022 3.25 Bn
Jun 30, 2022 3.95 Bn
Mar 31, 2022 4.31 Bn
Dec 31, 2021 3.82 Bn
Sep 30, 2021 4.57 Bn
API Access

Merck Income from Continuing Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=MRK&period=max&api_key=YOUR_API_KEY